GLO1 and how it affects obesity, type 2 diabetes, and fatty liver disease
Glyoxalase 1 and its Role in Metabolic Syndrome
This project tests whether changing the enzyme GLO1 can protect adults who have or are at risk for obesity, type 2 diabetes, and fatty liver disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-11290384 on NIH RePORTER |
What this research studies
The researchers use genetic tools and diet models in animals to study how the enzyme GLO1 influences weight gain, blood sugar control, and liver fat. They created mice lacking GLO1 and compare them to normal mice on high-fat, high-sugar diets to see differences in weight, glucose tolerance, and liver steatosis. The team measures levels of the metabolic byproduct methylglyoxal (MGO), looks at gene activity linked to metabolism, and uses those findings to guide ideas for future human treatments. Results from these lab and animal experiments would inform whether targeting GLO1 could be a route to new therapies for metabolic disease.
Who could benefit from this research
Good fit: People most relevant would be adults with overweight/obesity, prediabetes or type 2 diabetes, or diagnosed non-alcoholic fatty liver disease.
Not a fit: People without metabolic disease or whose conditions are driven by unrelated causes may not benefit from approaches targeting GLO1.
Why it matters
Potential benefit: If successful, this work could point to new ways to prevent or treat obesity, type 2 diabetes, and non-alcoholic fatty liver disease by targeting GLO1 or its metabolic pathway.
How similar studies have performed: Early animal experiments from this team show protective effects when GLO1 is reduced, but translation to human treatments remains untested.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Galligan, James J — University of Arizona
- Study coordinator: Galligan, James J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.